Beyond the nine tumor reports, the broader narrative in the provided materials links Zolgensma’s newly confirmed cases to the ongoing debate about whether AAV vectors can drive cancer in rare instances. Multiple sources emphasize that vector DNA integration evidence has now appeared in at least some cases. For gene-therapy manufacturers and regulators, this is a reminder that long-term risk management is not purely theoretical, even when product labels already include integration-related risk language. The developments also highlight the importance of coordinated health-authority notification processes and the translation of mechanistic risk into monitoring protocols that patients and clinicians can understand.